Methods Project 4: Clinical Trial - Amended
Status: | Completed |
---|---|
Conditions: | Smoking Cessation |
Therapuetic Areas: | Pulmonary / Respiratory Diseases |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 5/5/2018 |
Start Date: | May 2015 |
End Date: | February 2018 |
Project 4: Clinical Trial Method for Assessing a Tobacco Product Part of Models for Tobacco Product Evaluation:
Cigarette smokers will be randomized to E-cigarette, Nicotine Gum or Lozenge, or Control
Group. Participants will enter a 1 week sampling phase. Smokers interested in continuing with
the study after the sampling phase will undergo a 2 week baseline assessment phase and will
then enter an 8 week intervention. Tobacco use patterns, subjective responses to product, and
nicotine and toxicant exposure will be assessed.
Group. Participants will enter a 1 week sampling phase. Smokers interested in continuing with
the study after the sampling phase will undergo a 2 week baseline assessment phase and will
then enter an 8 week intervention. Tobacco use patterns, subjective responses to product, and
nicotine and toxicant exposure will be assessed.
Sampling period (1 week): Subjects will be randomized to an alternative nicotine product
(E-cigarette, Nicotine Gum or Lozenge) or assigned to continue smoking their usual brand
cigarettes. Subjects will complete screening assessments, asked to sample the assigned
product and start recording their cigarette or other tobacco intake on a daily basis using an
interactive voice response system (IVR). Smokers assigned to the control condition (smoking
usual brand cigarettes) will be asked to choose the product that they would like to sample.
Baseline smoking period: After sampling, subjects who meet specific criteria will continue
with the experimental intervention phase. These subjects will be required to attend 2
baseline clinic visits where baseline assessments will be captured. Records of their
cigarette or other tobacco intake on a daily basis will continue using the interactive voice
response system (IVR).
Experimental Period: After the baseline assessment, subjects will be instructed to either
partially or completely substitute their cigarette smoking with their assigned product. They
will assigned to one of six experimental conditions:
1. smoking usual brand cigarette controls, who after 8-weeks will be offered any of the
other nicotine products to use as they choose for 8 weeks;
2. complete substitution (i.e., no smoking) with an E-cigarette;
3. partial substitution with an E-cigarette;
4. complete substitution (i.e., no smoking) with nicotine gum or nicotine lozenge.
The assigned product, E-cigarette, Nic Gum or Lozenge, but not usual brand cigarettes, will
be provided to subjects at the clinic visits. Subjects will attend clinic visits over the
next 8 weeks where tobacco use patterns and biomarker data will be collected.
(E-cigarette, Nicotine Gum or Lozenge) or assigned to continue smoking their usual brand
cigarettes. Subjects will complete screening assessments, asked to sample the assigned
product and start recording their cigarette or other tobacco intake on a daily basis using an
interactive voice response system (IVR). Smokers assigned to the control condition (smoking
usual brand cigarettes) will be asked to choose the product that they would like to sample.
Baseline smoking period: After sampling, subjects who meet specific criteria will continue
with the experimental intervention phase. These subjects will be required to attend 2
baseline clinic visits where baseline assessments will be captured. Records of their
cigarette or other tobacco intake on a daily basis will continue using the interactive voice
response system (IVR).
Experimental Period: After the baseline assessment, subjects will be instructed to either
partially or completely substitute their cigarette smoking with their assigned product. They
will assigned to one of six experimental conditions:
1. smoking usual brand cigarette controls, who after 8-weeks will be offered any of the
other nicotine products to use as they choose for 8 weeks;
2. complete substitution (i.e., no smoking) with an E-cigarette;
3. partial substitution with an E-cigarette;
4. complete substitution (i.e., no smoking) with nicotine gum or nicotine lozenge.
The assigned product, E-cigarette, Nic Gum or Lozenge, but not usual brand cigarettes, will
be provided to subjects at the clinic visits. Subjects will attend clinic visits over the
next 8 weeks where tobacco use patterns and biomarker data will be collected.
Inclusion Criteria:
- Male or female subjects who are at least 18 years of age;
- Daily smoker;
- Generally good health;
- Subject has provided written informed consent to participate in the study (adolescents
under the age of 18 will be excluded because this project involves continued use of
tobacco products and new tobacco products);
Exclusion Criteria:
- Unstable health;
- Pregnant or breastfeeding (due to toxic effects from tobacco products);
- Unable to read for comprehension or completion of study documents.
We found this trial at
3
sites
Click here to add this to my saved trials
425 E River Pkwy # 754
Minneapolis, Minnesota 55455
Minneapolis, Minnesota 55455
612-624-2620
Masonic Cancer Center at University of Minnesota The Masonic Cancer Center was founded in 1991....
Click here to add this to my saved trials
Click here to add this to my saved trials